ClinicalTrials.gg
CompletedNCT00529100Updated Jul 9, 2013Results posted

Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

A Phase 1/2 interventional study of Pemetrexed Phase 1 and Cisplatin Phase 1 in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-09.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
126th of 223
49 · median 64
Started
2005
with 19 others
Phase 1/2
17 of 227
2 open now
Registered
62nd of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 126th largest by enrollment of the 223 interventional ones that give a count, is one of 20 that started in 2005, is one of 17 in phase 1/2, and was the 62nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Some of the requirements to be in this study are:

  • Patient must be at least 18 years old.
  • Patient must have been diagnosed with non-small cell lung cancer.
  • Patient must be able to visit the doctor's office once a week.
  • Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.
  • Female patients of must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of during and for 3 months following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

Patients cannot participate in this study for any of the following reasons:

  • Patient has previously had chemotherapy.
  • Patient has previously had thoracic radiation therapy.
  • Patient has received treatment within the last 30 days with a drug that has not received approval by Health Canada for any indication at the time of study entry.
  • Female patient is pregnant or breast-feeding.
  • Patient is unsuitable to participate in the study in the opinion of the investigator.
  • Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Pemetrexed/Cisplatin/Radiation Phase 1

    Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m\^2) IV through 500 mg/m\^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m\^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m\^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m\^2 IV and cisplatin 75 mg/m\^2 IV.

    Drug: Pemetrexed Phase 1 · Drug: Cisplatin Phase 1 · Procedure: Radiation Therapy

  • Experimental
    Pemetrexed/Cisplatin/Radiation Phase 2

    Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m\^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m\^2 IV and cisplatin 75 mg/m\^2 IV.

    Procedure: Radiation Therapy · Drug: Pemetrexed Phase 2 · Drug: Cisplatin Phase 2

Interventions

  • 300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles

    Also known as: LY231514, Alimta

  • DrugCisplatin Phase 1

    Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.

  • ProcedureRadiation Therapy

    Phases 1 and 2: 61-65 Gy in 33-35 fractions

  • Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.

    Also known as: LY231514, Alimta

  • DrugCisplatin Phase 2

    Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy

    Recommended Phase 2 MTD was highest dose at which no more than 1 of 6 participants experienced dose level toxicity (DLT). DLT=(1) Grade 3/4 dysphagia/esophagitis, leukopenia, thrombocytopenia, febrile neutropenia, fatigue/malaise, pneumonitis, dermatitis, persistent elevation of bilirubin/alkaline phosphatase/aspartate aminotransferase only if resulting in delay of radiotherapy \>1 week, delay of pemetrexed/cisplatin Cycle 2 \>2 weeks, or delay of pemetrexed/cisplatin Cycle 3 past 5 weeks after radiotherapy; (2) other Grade 3 or 4 toxicity possibly related to concurrent treatment administration.

    Time frame: Baseline to measured progressive disease (PD; up to 1 year)

  2. Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year

    OS was defined as the time from date of enrollment to death due to any cause.

    Time frame: Baseline to date of death from any cause (up to 1 year)

Secondary outcomes

  1. Phase 1: Number of Participants With Adverse Events (AE; Toxicity)

    A listing of AEs is located in the Reported Adverse Event module.

    Time frame: Baseline to measured PD (up to 1 year)

  2. Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years

    OS was defined as the time from date of enrollment to death due to any cause.

    Time frame: Baseline and 2 years and 3 years

  3. Phase 2: Time to Progressive Disease (PD)

    Time to PD was defined as the time from study enrollment to the first date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions. Time to PD was censored at the date of death if death was due to other cause. For participants not known to have died as of the data cut-off date and who did not have PD, time to PD was censored at the last progression-free disease assessment. For participants who received subsequent cancer therapy (after discontinuation from the study therapy) before PD, time to PD was censored at the date of subsequent cancer therapy initiation.

    Time frame: Baseline to measured PD (up to 3 years)

  4. Phase 2: Percentage of Participants With Progression Free Survival (PFS)

    The percentage of participants not known to have died as of the data cut-off date or last contact and who did not have PD.

    Time frame: Baseline and 1 year and 2 years and 3 years

  5. Progression Free Survival (PFS)

    PFS was defined as the period from study entry until PD, death, or date of last contact. For participants not known to have died as of the data cut-off date and who did not have PD, the PFS date was censored at the last contact date (contacts considered in the determination of last progression free disease assessment).

    Time frame: Baseline to measured PD (up to 36 months)

  6. Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)

    Response using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Objective response rate (%)=number of objective responders divided by the number of participants with measurable disease \* 100, where objective responders are those participants who have met criteria either for CR or PR.

    Time frame: Baseline to measured PD (up to 3 years)

  7. Phase 2: Site of Progressive Disease (PD)

    Summarized participants with local (progression within the sites of initial disease)/regional (disease progression adjacent to but not within the site of initial disease at the start of treatment), distant (disease progression that is blood borne to other parts of the body, including outside the chest or involving the contralateral lung), and local + distant sites of disease. Objective PD is defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions.

    Time frame: Baseline to measured PD (up to 3 years)

07

Results

Posted Sep 28, 2011

Participant flow

Participant flow — Overall Study
MilestonePemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 2
Started1633
Received at least 1 dose of study drug1633
Completed1624
Not completed09
Withdrew: Adverse event05
Withdrew: Protocol violation01
Withdrew: Progressive disease01
Withdrew: Withdrawal by subject01
Withdrew: Participant ineligibility01

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy

Recommended Phase 2 MTD was highest dose at which no more than 1 of 6 participants experienced dose level toxicity (DLT). DLT=(1) Grade 3/4 dysphagia/esophagitis, leukopenia, thrombocytopenia, febrile neutropenia, fatigue/malaise, pneumonitis, dermatitis, persistent elevation of bilirubin/alkaline phosphatase/aspartate aminotransferase only if resulting in delay of radiotherapy \>1 week, delay of pemetrexed/cisplatin Cycle 2 \>2 weeks, or delay of pemetrexed/cisplatin Cycle 3 past 5 weeks after radiotherapy; (2) other Grade 3 or 4 toxicity possibly related to concurrent treatment administration.

Time frame:
Baseline to measured progressive disease (PD; up to 1 year)
Reported as:
Number · milligrams per square meter (mg/m^2)
Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy
milligrams per square meter (mg/m^2)Pemetrexed/Cisplatin/Radiation Phase 1
Concurrent Phase MTD: Pemetrexed500
Concurrent Phase MTD: Cisplatin20
Consolidation Phase MTD: Pemetrexed500
Consolidation Phase MTD: Cisplatin75
PrimaryPhase 2: Percentage of Participants With Overall Survival (OS) at 1 Year

OS was defined as the time from date of enrollment to death due to any cause.

Time frame:
Baseline to date of death from any cause (up to 1 year)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year
percentage of participantsPemetrexed/Cisplatin/Radiation Phase 2
Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year79.0 (66.1 to 92.0)
SecondaryPhase 1: Number of Participants With Adverse Events (AE; Toxicity)

A listing of AEs is located in the Reported Adverse Event module.

Time frame:
Baseline to measured PD (up to 1 year)
Reported as:
Number · participants
Phase 1: Number of Participants With Adverse Events (AE; Toxicity)
participantsPemetrexed/Cisplatin/Radiation Phase 1
Serious Adverse Events (SAEs)5
Other Non-serious Adverse Events (AEs)10
SecondaryPhase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years

OS was defined as the time from date of enrollment to death due to any cause.

Time frame:
Baseline and 2 years and 3 years
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years
percentage of participantsPemetrexed/Cisplatin/Radiation Phase 2
2 years56.4 (40.8 to 72.0)
3 years46.2 (30.5 to 61.8)
SecondaryPhase 2: Time to Progressive Disease (PD)

Time to PD was defined as the time from study enrollment to the first date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions. Time to PD was censored at the date of death if death was due to other cause. For participants not known to have died as of the data cut-off date and who did not have PD, time to PD was censored at the last progression-free disease assessment. For participants who received subsequent cancer therapy (after discontinuation from the study therapy) before PD, time to PD was censored at the date of subsequent cancer therapy initiation.

Time frame:
Baseline to measured PD (up to 3 years)
Reported as:
Median · months
Phase 2: Time to Progressive Disease (PD)
monthsPemetrexed/Cisplatin/Radiation Phase 2
Phase 2: Time to Progressive Disease (PD)13.7 (10.2 to 19.2)
SecondaryPhase 2: Percentage of Participants With Progression Free Survival (PFS)

The percentage of participants not known to have died as of the data cut-off date or last contact and who did not have PD.

Time frame:
Baseline and 1 year and 2 years and 3 years
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Progression Free Survival (PFS)
percentage of participantsPemetrexed/Cisplatin/Radiation Phase 2
1 Year48.7 (33.0 to 64.4)
2 Years30.8 (16.3 to 45.3)
3 Years20.2 (7.5 to 32.9)
SecondaryProgression Free Survival (PFS)

PFS was defined as the period from study entry until PD, death, or date of last contact. For participants not known to have died as of the data cut-off date and who did not have PD, the PFS date was censored at the last contact date (contacts considered in the determination of last progression free disease assessment).

Time frame:
Baseline to measured PD (up to 36 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPemetrexed/Cisplatin/Radiation Phase 2
Progression Free Survival (PFS)11.8 (9.8 to 19.2)
SecondaryPhase 2: Percentage of Participants With Objective Tumor Response (Response Rate)

Response using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Objective response rate (%)=number of objective responders divided by the number of participants with measurable disease \* 100, where objective responders are those participants who have met criteria either for CR or PR.

Time frame:
Baseline to measured PD (up to 3 years)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)
percentage of participantsPemetrexed/Cisplatin/Radiation Phase 2
Complete Response0 (0 to 0)
Partial Response45.95 (29.89 to 62.00)
SecondaryPhase 2: Site of Progressive Disease (PD)

Summarized participants with local (progression within the sites of initial disease)/regional (disease progression adjacent to but not within the site of initial disease at the start of treatment), distant (disease progression that is blood borne to other parts of the body, including outside the chest or involving the contralateral lung), and local + distant sites of disease. Objective PD is defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions.

Time frame:
Baseline to measured PD (up to 3 years)
Reported as:
Number · participants
Phase 2: Site of Progressive Disease (PD)
participantsPemetrexed/Cisplatin/Radiation Phase 2
Local/Regional8
Distant17
Local + Distant1
Unknown1

Adverse events

Collected over Serious Adverse Events (SAE) and other Non-Serious Adverse Events were collected during study treatment only, participants received study drug for 4 cycles of 21 days per cycle.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed/Cisplatin/Radiation Phase 1—5/10 (50%)10/10 (100%)
Pemetrexed/Cisplatin/Radiation Phase 1-2—0/6 (0%)6/6 (100%)
Pemetrexed/Cisplatin/Radiation Phase 2—9/33 (27.3%)33/33 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-2Pemetrexed/Cisplatin/Radiation Phase 2
Oedema peripheralGeneral disorders2/100/60/33
OesophagitisGastrointestinal disorders1/100/62/33
Enterocolitis infectiousInfections and infestations1/100/60/33
Vascular access complicationInjury, poisoning and procedural complications1/100/60/33
Blood creatinine increasedInvestigations1/100/60/33
Haemoglobin decreasedInvestigations1/100/60/33
DehydrationMetabolism and nutrition disorders1/100/61/33
Pain in extremityMusculoskeletal and connective tissue disorders1/100/60/33
HypertensionVascular disorders1/100/60/33
FatigueGeneral disorders0/100/62/33
Most frequent other events
Showing 10 of 138
Most frequent other events
EventPemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-2Pemetrexed/Cisplatin/Radiation Phase 2
LymphopeniaBlood and lymphatic system disorders0/106/628/33
FatigueGeneral disorders9/106/630/33
Lymphocyte count decreasedInvestigations10/100/60/33
Neutrophil count decreasedInvestigations9/106/624/33
Platelet count decreasedInvestigations8/106/616/33
White blood cell count decreasedInvestigations9/106/627/33
CoughRespiratory, thoracic and mediastinal disorders10/102/615/33
Blood glucose increasedInvestigations9/100/60/33
Haemoglobin decreasedInvestigations9/105/626/33
NauseaGastrointestinal disorders6/102/628/33

Baseline characteristics

All participants who received study drug in Phase 1, Phase 1 and 2, or Phase 2.

Age Continuous
Age Continuous(years)Pemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2Pemetrexed/Cisplatin/Radiation Phase 2Total
Mean60.3 ± 8.064.3 ± 8.161.2 ± 10.561.4 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2Pemetrexed/Cisplatin/Radiation Phase 2Total
Female631827
Male431522
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2Pemetrexed/Cisplatin/Radiation Phase 2Total
Hispanic or Latino0000
Not Hispanic or Latino1063046
Unknown or Not Reported0033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2Pemetrexed/Cisplatin/Radiation Phase 2Total
American Indian or Alaska Native0000
Asian1146
Native Hawaiian or Other Pacific Islander0000
Black or African American0022
White952741
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Pemetrexed/Cisplatin/Radiation Phase 1Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2Pemetrexed/Cisplatin/Radiation Phase 2Total
Canada1063349
08

Study locations

4 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edmonton, Alberta T6G 1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamilton, Ontario L8V 5C2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottawa, Ontario K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M5G 2M9, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Aug 2010 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2007
First posted
Sep 14, 2007
Start
Dec 2005
Primary completionActual
Aug 2010
CompletionActual
Sep 2012
Results first posted
Sep 28, 2011
Last update
Jul 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00529100
Responsible party
Sponsor
First posted
Sep 14, 2007
Start date
Dec 2005
Primary completion
Aug 2010
Completion
Sep 2012
Results posted
Sep 28, 2011
Last update
Jul 9, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT- 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion